ArticleNucleic acids research2025
ASOptimizer: optimizing chemical diversity of antisense oligonucleotides through deep learning.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics.Current issues in molecular biology · 2026Review
- Artificial intelligence in biologic drug discovery: A review of methodological evolution and therapeutic applications.Acta pharmaceutica Sinica. B · 2026Review
- QStrain: an interactive platform for viral genome analysis and nucleic acid therapeutic design.BMC bioinformatics · 2026Article
- Unlocking the undruggable spliceosome: generative AI and structural dynamics in cancer therapy.Frontiers in cell and developmental biology · 2026Review
- Application of Antisense Oligonucleotides as an Alternative Approach for Gene Expression Control and Functional Studies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antisense oligonucleotides (ASOs) are a promising class of gene therapies that can modulate the gene expression. However, designing ASOs manually is resource-intensive and time-consuming. To address this, we introduce a user-friendly web server for ASOptimizer, a deep learning-based computational framework for optimizing ASO sequences and chemical modifications. Given a user-provided ASO sequence, the web server systematically explores modification sites within the nucleic acid and returns a ranked list of promising modification patterns. With an intuitive interface requiring no expertise in deep learning tools, the platform makes ASOptimizer easily accessible to the broader research community. The web server is freely available at https://asoptimizer.s-core.ai/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.